Integra Lifesciences Holdings Corp (IART) Stock AnalysisIARTStock AnalysisIntegra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Integra Lifesciences Holdings Corp (IART) is currently priced at $16.89, which is below the analyst price target of $19, suggesting potential for growth. However, the stock has a low RSI of 41.889, indicating it is nearing oversold territory, which could signal a buying opportunity if momentum shifts. The forward P/E ratio is 6.8634, suggesting the stock is undervalued compared to future earnings expectations. However, the company has faced significant net income losses in recent quarters, with a net income of -4.6 million in Q1 2026 and -4.5 million in Q2 2026, raising concerns about profitability. The main risk is the company's high debt-to-equity ratio of 179.45%, which could limit financial flexibility and growth potential.

15 analysts cover IART: 9 rate it Buy, 6 Hold and 0 Sell. The average price target is 12.33.